Loading organizations...
Jilin Aodong Pharmaceutical Group develops and manufactures traditional Chinese pharmaceuticals and related packaging products. The company focuses on proprietary Chinese medicines, applying established practices for healthcare solutions. Beyond pharma, Jilin Aodong also operates toll roads and engages in deer raising, demonstrating a diversified business portfolio.
Established in 1993, Jilin Aodong Pharmaceutical Group quickly became a significant player in China's pharmaceutical sector. Mr. Li Xiulin, a key chairman, notably guided the company's development. Its founding as a state-owned enterprise reflected a strategic move to commercialize and expand traditional Chinese medicine for the domestic market.
Serving the vast Chinese market, Jilin Aodong provides accessible pharmaceutical products. Its vision centers on solidifying its position in traditional Chinese medicine while prudently diversifying into other economic segments. This approach aims to ensure sustained growth and broad contributions to public health.
Ji Lin Ao Dong has 1 tracked investment across 1 company. The latest tracked deal is $45.0M Series A in Thousand Oaks Biopharmaceuticals in January 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 3, 2019 | Thousand Oaks Biopharmaceuticals | $45.0M Series A | Liefeng Qu | Blue Bay Capital, Qianrong Holdings, Tenyall & Sumin |